Research Analysts Set Expectations for HRMY FY2029 Earnings

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) – HC Wainwright issued their FY2029 earnings per share estimates for Harmony Biosciences in a research report issued on Thursday, January 16th. HC Wainwright analyst P. Trucchio forecasts that the company will post earnings of $5.99 per share for the year. HC Wainwright has a “Buy” rating and a $75.00 price objective on the stock. The consensus estimate for Harmony Biosciences’ current full-year earnings is $2.43 per share.

Harmony Biosciences (NASDAQ:HRMY) last announced its quarterly earnings data on Tuesday, October 29th. The company reported $0.79 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.15. The company had revenue of $186.00 million during the quarter, compared to the consensus estimate of $184.07 million. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The firm’s revenue was up 16.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.63 EPS.

A number of other equities research analysts have also recently commented on HRMY. Mizuho raised their price target on Harmony Biosciences from $42.00 to $52.00 and gave the company an “outperform” rating in a report on Thursday, October 10th. Raymond James reissued an “outperform” rating and set a $40.00 target price on shares of Harmony Biosciences in a research note on Thursday, October 10th. Needham & Company LLC reaffirmed a “buy” rating and set a $52.00 price objective on shares of Harmony Biosciences in a report on Monday, January 13th. Oppenheimer reiterated an “outperform” rating and set a $59.00 price objective (up previously from $56.00) on shares of Harmony Biosciences in a research report on Wednesday, October 30th. Finally, Cantor Fitzgerald upped their target price on shares of Harmony Biosciences from $51.00 to $58.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 30th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $55.00.

Harmony Biosciences Stock Up 3.6 %

Shares of HRMY stock opened at $40.46 on Monday. The company has a market capitalization of $2.31 billion, a price-to-earnings ratio of 19.18, a PEG ratio of 0.54 and a beta of 0.78. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.24 and a quick ratio of 3.20. The company’s fifty day moving average price is $34.46 and its 200-day moving average price is $34.96. Harmony Biosciences has a one year low of $28.14 and a one year high of $41.61.

Insider Buying and Selling

In other Harmony Biosciences news, insider Jeffrey Dierks sold 1,123 shares of the business’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $40.00, for a total transaction of $44,920.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Over the last quarter, insiders sold 33,126 shares of company stock worth $1,303,727. Corporate insiders own 30.80% of the company’s stock.

Hedge Funds Weigh In On Harmony Biosciences

Large investors have recently made changes to their positions in the company. GAMMA Investing LLC lifted its holdings in Harmony Biosciences by 92.6% during the 4th quarter. GAMMA Investing LLC now owns 907 shares of the company’s stock valued at $31,000 after buying an additional 436 shares in the last quarter. Mendota Financial Group LLC raised its stake in shares of Harmony Biosciences by 24,125.0% during the fourth quarter. Mendota Financial Group LLC now owns 969 shares of the company’s stock valued at $33,000 after acquiring an additional 965 shares in the last quarter. CWM LLC boosted its holdings in shares of Harmony Biosciences by 111.7% in the third quarter. CWM LLC now owns 1,469 shares of the company’s stock valued at $59,000 after purchasing an additional 775 shares during the period. Quarry LP purchased a new position in Harmony Biosciences during the 2nd quarter worth $62,000. Finally, Quantbot Technologies LP bought a new stake in Harmony Biosciences during the 3rd quarter valued at $74,000. 86.23% of the stock is owned by hedge funds and other institutional investors.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.